Vaccines against human papillomavirus and perspectives for the prevention and control of cervical cancer

Salud Publica de Mexico

Volumn 45, Issue SUPPL. 3, 2003, Pages

  García Carrancá, Alejandro ^a,b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Cervical cancer; Human papillomavirus; Immunity; Perspectives; Prophylactic vaccines; Therapeutic vaccines

Indexed keywords

DNA VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER PREVENTION; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOGENICITY; MINIMAL RESIDUAL DISEASE; PERSISTENT INFECTION; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REVIEW; UTERINE CERVIX CANCER; VIRION; VIRUS PARTICLE; WART VIRUS;

EID: 0346789512     PISSN: 00363634     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0036-36342003000900018     Document Type: Review

References (29)

1. zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer. 2002. 2:342-350.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer-worldwide. J Pathol. 1999. 189:12-19.
3. Frazer IH. Vaccines for papillomavirus infection. Virus Res. 2002. 89:271-274.
4. Zhou J, Sun XY, Stenzel DJ, Frazer IH. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology. 1991. 185:251-257.
5. Ault KA. Virus-like particles as a potential vaccine for human papillomavirus. Papillomavirus Rep. 2003;14:47-51.
6. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A. 1995. 92:11553-11557.
7. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C et al. Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-3963.
8. Kirnbauer R, Chandrachud LM, O'Neil BW, Wagner ER, Grindlay GJ, Armstrong A et al. Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 1996. 219:37-44.
9. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 LI virus-like particule vaccine. J Natl Cancer Inst 2001; 93:284-292.
10. Giroglou T, Sapp M, Lane C, Fligge C, Christensen ND, Streeck RE, Rose RC. Immunological analyses of human papillomavirus capsids. Vaccine 2001;19:1783-93.
11. Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA et al. A Phase I study of a recombinant viruslike particule vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 2001; 183:1485-1493.
12. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-1651.
13. DeFilippis RA, Goodwin EC, Wu L, DiMaio D. Endogenous human papillomavirus E6 and E7 proteins differentially regulate proliferation, senescence, and apoptosis in HeLa cervical carcinoma cells. J Virol 2003; 77:1551-1563.
14. Borysiewicz LK, Fiander A, Nimako M, Man S, Wilkinson GW, Westmoreland D et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-1527.
15. Muderspach L, Wilczynski S, Roman L, Bade L, Felix J, Small LA et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin Cancer Res 2000;6:3406-3416.
16. Steller MA, Gurski KJ, Murakami M, Daniel RW, Shah KV, Celis E et al. Cell-mediated immunological responses in cervical and vaginal-cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin Cancer Res. 1998. 4:2103-2109.
17. de Jong A, O'Neill T, Khan AY, Kwappenberg KM, Chisholm SE, Whittle NR et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPVI 6 L2E7E6 fusion protein vaccine. Vaccine 2002;20:3456-3464.
18. van der Burg SH, Kwappenberg KM, O'Neill T, Brandt RM, Melief CJ, Hickling JK et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 2001;19:3652-3660.
19. Mendoza L, Bubenik J, Simova J, Jandlova T, Vonka V, Mikyskova R. Prophylactic, therapeutic and anti-metastatic effects of BMDC and DC lines in mice carrying HPV 16-associated tumours. Int J Oncol 2003;23:243-247.
20. Muller M, Zhou J, Reed TD, Rittmuller C, Burger A, Gabelsberger J et al. Chimeric papillomavirus-like particles. Virology 1997;234:93-111.
21. Nieland JD, Da Silva DM, Velders MP, de Visser KE, Schiller JT, Muller M et al. Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J Cell Biochem 1999;73:145-152.
22. Da Silva DM, Schiller JT, Kast WM. Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine 2003;21:3219-3227.
23. Berumen J, Casas L, Segura E, Amezcua JL, Garcia-Carrancá A. Genome amplification of human papillomavirus types 16 and 18 in cervical carcinomas is related to the retention of E1/E2 genes. Int J Cancer 1994; 56:640-645.
24. Desaintes C, Demeret C, Goyat S, Yaniv M, Thierry F. Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. EMBO J 1997. 16:504-514.
25. Demeret C, Garcia-Carrancá A, Thierry F. Transcription-independent triggering of the extrinsic pathway of apoptosis by human papillomavirus 18 E2 protein. Oncogene 2003;22:168-175.
26. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997;15:617-648.
27. Cichutek K. DNA vaccines: development, standardization and regulation. Intervirology 2000;43:331-338.
28. Rocha-Zavaleta L, Alejandre J, Garcia-Carrancá A. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses. J Med Virol 2002;66:86-95.
29. Plummer M, Franceschi S. Strategies for HPV prevention. Virus Res 2002;89:285-293.